Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:ATHE NASDAQ:CRDL NASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$5.82-1.5%$6.12$4.50▼$11.54$128.68M2.3634,023 shs45,519 shsATHEAlterity Therapeutics$3.90$4.14$2.66▼$7.00$34.58M0.321,441 shs11,541 shsCRDLCardiol Therapeutics$1.11-3.5%$1.33$0.88▼$1.71$132.53M0.72382,467 shs427,263 shsSPRBSpruce Biosciences$50.43-5.2%$58.51$4.35▼$240.00$146.34M3.1148,161 shs33,873 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-2.80%-0.51%-7.37%+2.07%-38.24%ATHEAlterity Therapeutics-2.00%-3.68%-13.25%+14.58%-17.26%CRDLCardiol Therapeutics+2.68%-10.16%-12.21%+18.46%-20.69%SPRBSpruce Biosciences+8.40%+8.09%-10.40%-4.83%+1,077.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$5.82-1.5%$6.12$4.50▼$11.54$128.68M2.3634,023 shs45,519 shsATHEAlterity Therapeutics$3.90$4.14$2.66▼$7.00$34.58M0.321,441 shs11,541 shsCRDLCardiol Therapeutics$1.11-3.5%$1.33$0.88▼$1.71$132.53M0.72382,467 shs427,263 shsSPRBSpruce Biosciences$50.43-5.2%$58.51$4.35▼$240.00$146.34M3.1148,161 shs33,873 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-2.80%-0.51%-7.37%+2.07%-38.24%ATHEAlterity Therapeutics-2.00%-3.68%-13.25%+14.58%-17.26%CRDLCardiol Therapeutics+2.68%-10.16%-12.21%+18.46%-20.69%SPRBSpruce Biosciences+8.40%+8.09%-10.40%-4.83%+1,077.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$14.67152.00% UpsideATHEAlterity Therapeutics 2.00HoldN/AN/ACRDLCardiol Therapeutics 2.33Hold$8.50665.77% UpsideSPRBSpruce Biosciences 2.50Moderate Buy$176.60250.19% UpsideCurrent Analyst Ratings BreakdownLatest ATHE, CRDL, SPRB, and ACOG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026SPRBSpruce Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$200.00 ➝ $150.005/29/2026ACOGAlpha Cognition Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/27/2026SPRBSpruce Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026ACOGAlpha Cognition HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.005/14/2026SPRBSpruce Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$170.00 ➝ $150.004/27/2026ACOGAlpha Cognition HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/27/2026SPRBSpruce Biosciences Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$140.004/20/2026ATHEAlterity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026ACOGAlpha Cognition Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.004/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/10/2026SPRBSpruce Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$180.00 ➝ $170.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha Cognition$10.22M12.40N/AN/A$2.88 per share2.02ATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/ACRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/ASPRBSpruce Biosciences$4.91M28.24N/AN/A$39.72 per share1.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$20.67M-$1.35N/AN/AN/A-232.23%-58.35%-45.99%8/13/2026 (Estimated)ATHEAlterity Therapeutics-$7.87MN/AN/AN/AN/AN/AN/AN/AN/ACRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)SPRBSpruce Biosciences-$38.97M-$36.60N/AN/AN/AN/A-155.40%-101.67%8/13/2026 (Estimated)Latest ATHE, CRDL, SPRB, and ACOG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ACOGAlpha Cognition-$0.41-$0.37+$0.04-$0.32$3.42 million$3.53 million5/13/2026Q1 2026SPRBSpruce Biosciences-$7.9340-$8.94-$1.0060-$8.94N/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/A3/26/2026Q4 2025ACOGAlpha Cognition-$0.27-$0.30-$0.03-$0.31$4.41 million$2.79 million3/12/2026Q4 2025SPRBSpruce Biosciences-$9.1575-$9.58-$0.4225-$9.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A12.6411.52ATHEAlterity TherapeuticsN/A21.97N/ACRDLCardiol TherapeuticsN/A4.394.39SPRBSpruce Biosciences0.164.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AATHEAlterity Therapeutics2.14%CRDLCardiol Therapeutics12.49%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%ATHEAlterity Therapeutics38.80%CRDLCardiol Therapeutics5.25%SPRBSpruce Biosciences4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A21.77 million18.73 millionN/AATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableSPRBSpruce Biosciences202.75 million2.63 millionOptionableATHE, CRDL, SPRB, and ACOG HeadlinesRecent News About These CompaniesSpruce Biosciences Announces Data Presentation at the 18th International MPS SymposiumMay 28, 2026 | businesswire.comSpruce Biosciences to Participate in Upcoming Conferences in JuneMay 27, 2026 | businesswire.comSpruce Biosciences Stockholders Approve Directors and Annual Say-on-PayMay 26, 2026 | tipranks.comSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | businesswire.comSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President ...May 4, 2026 | bakersfield.comBCraig-Hallum initiates coverage of Spruce Biosciences (SPRB) with buy recommendationApril 28, 2026 | msn.comWhy is Spruce Biosciences stock sinking Tuesday?April 21, 2026 | msn.comSpruce Biosciences prices $60M public offering at $50.00 per shareApril 21, 2026 | msn.comSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | businesswire.comSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | finance.yahoo.comWall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to TradeApril 3, 2026 | zacks.comDoes Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?March 18, 2026 | zacks.comSpruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net LossMarch 17, 2026 | insidermonkey.comSpruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial OfficerMarch 9, 2026 | pharmiweb.comPSpruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate UpdatesMarch 9, 2026 | businesswire.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | insidermonkey.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | msn.comSpruce Biosciences to Present at Upcoming Investor Conferences in MarchMarch 2, 2026 | businesswire.comSPRB stock drops after company pushes back application submission timeline for experimental Sanfilippo syndrome therapyFebruary 18, 2026 | msn.comSpruce Biosciences reports positive FDA meetings as it prepares TA-ERT filing for rare pediatric disorderFebruary 18, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?By Ryan Hasson | May 12, 2026Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 2026MongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today"By Sam Quirke | June 3, 2026ATHE, CRDL, SPRB, and ACOG Company DescriptionsAlpha Cognition NASDAQ:ACOG$5.82 -0.09 (-1.52%) Closing price 04:00 PM EasternExtended Trading$5.78 -0.04 (-0.60%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Alterity Therapeutics NASDAQ:ATHE$3.90 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.92 +0.02 (+0.51%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Cardiol Therapeutics NASDAQ:CRDL$1.11 -0.04 (-3.48%) Closing price 04:00 PM EasternExtended Trading$1.12 +0.01 (+0.90%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Spruce Biosciences NASDAQ:SPRB$50.43 -2.74 (-5.15%) Closing price 04:00 PM EasternExtended Trading$50.94 +0.51 (+1.00%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
